TY - JOUR
T1 - A prospective cohort multicenter study of molecular epidemiology and phylogenomics of Staphylococcus aureus bacteremia in nine Latin American countries
AU - Arias, Cesar A.
AU - Reyes, Jinnethe
AU - Carvajal, Lina Paola
AU - Rincon, Sandra
AU - Diaz, Lorena
AU - Panesso, Diana
AU - Ibarra, Gabriel
AU - Rios, Rafael
AU - Munita, Jose M.
AU - Salles, Mauro J.
AU - Alvarez-Moreno, Carlos
AU - Labarca, Jaime
AU - Garcia, Coralith
AU - Luna, Carlos M.
AU - Mejia-Villatoro, Carlos
AU - Zurita, Jeannete
AU - Guzman-Blanco, Manuel
AU - Rodriguez-Noriega, Eduardo
AU - Narechania, Apurva
AU - Rojas, Laura J.
AU - Planet, Paul J.
AU - Weinstock, George M.
AU - Gotuzzo, Eduardo
AU - Seas, Carlos
N1 - Funding Information:
All authors have completed and submitted the ICMJE form for the disclosure of potential conflicts of interest. Cesar A. Arias has received grant support, consulted for or provided lectures for Pfizer, Merck, Bayer, Allergan Pharmaceuticals, Novartis, Thera-vance, and the Medecins Company. Mauro J. Salles has received grant support from Pfizer and Novartis, and lecture and consulting fees from Pfizer, Novartis, Bayer, MSD, Sanofi-Aventis, and Astra-Zeneca. Paul J. Planet and Eduardo Rodríguez-Noriega have received lecture and consulting fees from Pfizer. Carlos Seas has received fees and grant support from Pfizer and grant support from Glaxo Smith Kline and Bristol Myers Squibb. No other conflict of interest was reported.
Funding Information:
This work was supported by an independent investigator-initiated grant to E.G. and C.S. C.A.A. is supported by the National Institutes of Health–National Institute of Allergy and Infectious Diseases (NIH/NIAID) (grants K24-AI114818, R01-AI093749, R21-AI114961, and R21/R33 AI121519). DNA sequencing was supported in part by Departamento de Ciencia, Tecnologia e Innovacion (COLCIENCIAS) (grant 130871250417/906-2015 to J.R.). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Publisher Copyright:
© 2017 American Society for Microbiology. All Rights Reserved.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017
Y1 - 2017
N2 - Staphylococcus aureus is an important pathogen causing a spectrum of diseases ranging from mild skin and soft tissue infections to life-threatening conditions. Bloodstream infections are particularly important, and the treatment approach is complicated by the presence of methicillin-resistant S. aureus (MRSA) isolates. The emergence of new genetic lineages of MRSA has occurred in Latin America (LA) with the rise and dissemination of the community-associated USA300 Latin American variant (USA300-LV). Here, we prospectively characterized bloodstream MRSA recovered from selected hospitals in 9 Latin American countries. All isolates were typed by pulsed-field gel electrophoresis (PFGE) and subjected to antibiotic susceptibility testing. Whole-genome sequencing was performed on 96 MRSA representatives. MRSA represented 45% of all (1,185 S. aureus) isolates. The majority of MRSA isolates belonged to clonal cluster (CC) 5. In Colombia and Ecuador, most isolates (72%) belonged to the USA300-LV lineage (CC8). Phylogenetic reconstructions indicated that MRSA isolates from participating hospitals belonged to three major clades. Clade A grouped isolates with sequence type 5 (ST5), ST105, and ST1011 (mostly staphylococcal chromosomal cassette mec [SCCmec] I and II). Clade B included ST8, ST88, ST97, and ST72 strains (SCCmec IV, subtypes a, b, and c/E), and clade C grouped mostly Argentinian MRSA belonging to ST30. In summary, CC5 MRSA was prevalent in bloodstream infections in LA with the exception of Colombia and Ecuador, where USA300-LV is now the dominant lineage. Clonal replacement appears to be a common phenomenon, and continuous surveillance is crucial to identify changes in the molecular epidemiology of MRSA.
AB - Staphylococcus aureus is an important pathogen causing a spectrum of diseases ranging from mild skin and soft tissue infections to life-threatening conditions. Bloodstream infections are particularly important, and the treatment approach is complicated by the presence of methicillin-resistant S. aureus (MRSA) isolates. The emergence of new genetic lineages of MRSA has occurred in Latin America (LA) with the rise and dissemination of the community-associated USA300 Latin American variant (USA300-LV). Here, we prospectively characterized bloodstream MRSA recovered from selected hospitals in 9 Latin American countries. All isolates were typed by pulsed-field gel electrophoresis (PFGE) and subjected to antibiotic susceptibility testing. Whole-genome sequencing was performed on 96 MRSA representatives. MRSA represented 45% of all (1,185 S. aureus) isolates. The majority of MRSA isolates belonged to clonal cluster (CC) 5. In Colombia and Ecuador, most isolates (72%) belonged to the USA300-LV lineage (CC8). Phylogenetic reconstructions indicated that MRSA isolates from participating hospitals belonged to three major clades. Clade A grouped isolates with sequence type 5 (ST5), ST105, and ST1011 (mostly staphylococcal chromosomal cassette mec [SCCmec] I and II). Clade B included ST8, ST88, ST97, and ST72 strains (SCCmec IV, subtypes a, b, and c/E), and clade C grouped mostly Argentinian MRSA belonging to ST30. In summary, CC5 MRSA was prevalent in bloodstream infections in LA with the exception of Colombia and Ecuador, where USA300-LV is now the dominant lineage. Clonal replacement appears to be a common phenomenon, and continuous surveillance is crucial to identify changes in the molecular epidemiology of MRSA.
KW - Bacteremia
KW - Latin America
KW - Staphylococcus aureus
UR - http://www.scopus.com/inward/record.url?scp=85029761800&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029761800&partnerID=8YFLogxK
U2 - 10.1128/AAC.00816-17
DO - 10.1128/AAC.00816-17
M3 - Article
C2 - 28760895
AN - SCOPUS:85029761800
VL - 61
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 10
ER -